Skip Navigation


NDT Advance Access originally published online on December 8, 2007
Nephrology Dialysis Transplantation 2008 23(4):1173-1178; doi:10.1093/ndt/gfm714
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/4/1173    most recent
gfm714v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moyses, Z. P.
Right arrow Articles by Magaldi, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moyses, Z. P.
Right arrow Articles by Magaldi, A. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Fluoxetine effect on kidney water reabsorption

Zenaide Providello Moyses, Fausto Kigui Nakandakari and Antonio José Magaldi

Laboratório de Pesquisa Básica-LIM 12, Laboratórios de Investigação Médica–Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil

Antonio José Magaldi, Faculdade de Medicina da USP, Av Dr Arnaldo, 455 s/3310, São Paulo-SP, CEP-01246-903, Brazil. Tel: +55-11-3061-7292; Fax: +55-11-3088-2267; E-mail: biomag{at}usp.br



  Abstract

Background. The pathogenesis of hyponatraemia caused by fluoxetine(Fx) use in the treatment of depression is not well understood. It has been attributed to a SIADH, although ADH-enhanced plasma level has not yet been demonstrated in all the cases reported in humans. This experiment aimed at investigating the effect of fluoxetine on the kidney and more specifically in the inner medullary collecting duct (IMCD).

Methods. (1) In vivo study: (a) 10 rats were injected daily i.p. with 10 mg/kg fluoxetine doses. After 10 days, rats were sacrificed and blood and kidneys were collected. (b) Immunoblotting studies for AQP2 protein expression in the IMCD from injected rats and in IMCD tubules suspension from 10 normal rats incubated with 10–7 M fluoxetine. (2) In vitro microperfusion study: The osmotic water permeability (Pf, µm/s) was determined in normal rats IMCD (n = 6), isolated and perfused by the standard methods.

Results. In vivo study: (a) Injected rats with fluoxetine lost about 12% body weight; Na+ plasma level decreased from 139.3 ± 0.78 mEq/l to 134.9 ± 0.5 mEq/l (p < 0.01) and K+ and ADH plasma levels remained unchanged. (b) Immunoblotting densitometric analysis of the assays showed an increase in AQP2 protein abundance of about 40%, both in IMCDs from injected rats [control period (cont) 99.6 ± 5.2 versus Fx 145.6 ± 16.9, p < 0.05] and in tubule suspension incubated with fluoxetine (cont 100.0 ± 3.5 versus 143.0 ± 2.0, p < 0.01). In vitro microperfusion study fluoxetine increased Pf in the IMCD in the absence of ADH from the cont 7.24 ± 2.07 to Fx 15.77 ± 3.25 (p < 0.01).

Conclusion. After fluoxetine use, the weight and plasma Na+ level decreased, and the K+ and ADH plasma levels remained unchanged, whereas the AQP2 protein abundance and water absorption in the IMCD increased, leading us to conclude that the direct effect of fluoxetine in the IMCD could explain at least in part, the hyponatraemia found sometime after this drug use in humans.

Keywords: AQP2; fluoxetine; hyponatraemia; water reabsorption

Received for publication: 9.12.06
Accepted in revised form: 12. 9.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NDT PlusHome page
N. van der Lubbe, C. J. Thompson, R. Zietse, and E. J. Hoorn
The clinical challenge of SIADH--three cases
NDT Plus, November 1, 2009; 2(suppl_3): iii20 - iii24.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
G. A. Campbell and M. H. Rosner
The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1852 - 1860.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.